These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36058362)

  • 1. The effects of walking in nature on negative and positive affect in adult psychiatric outpatients with major depressive disorder: A randomized-controlled study.
    Watkins-Martin K; Bolanis D; Richard-Devantoy S; Pennestri MH; Malboeuf-Hurtubise C; Philippe F; Guindon J; Gouin JP; Ouellet-Morin I; Geoffroy MC
    J Affect Disord; 2022 Dec; 318():291-298. PubMed ID: 36058362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interacting with nature improves cognition and affect for individuals with depression.
    Berman MG; Kross E; Krpan KM; Askren MK; Burson A; Deldin PJ; Kaplan S; Sherdell L; Gotlib IH; Jonides J
    J Affect Disord; 2012 Nov; 140(3):300-5. PubMed ID: 22464936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the (cost-) effectiveness of attention bias modification (ABM) for outpatients with major depressive disorder (MDD): a randomized controlled trial protocol.
    Ferrari GR; Becker ES; Smit F; Rinck M; Spijker J
    BMC Psychiatry; 2016 Nov; 16(1):370. PubMed ID: 27809880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complicated grief among individuals with major depression: prevalence, comorbidity, and associated features.
    Sung SC; Dryman MT; Marks E; Shear MK; Ghesquiere A; Fava M; Simon NM
    J Affect Disord; 2011 Nov; 134(1-3):453-8. PubMed ID: 21621849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of the 6min walk test in outpatients with bipolar disorder.
    Vancampfort D; Buys R; Sienaert P; Wyckaert S; De Herdt A; De Hert M; Probst M
    Psychiatry Res; 2015 Dec; 230(2):664-7. PubMed ID: 26526768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder.
    Cha DS; Best MW; Bowie CR; Gallaugher LA; Woldeyohannes HO; Soczynska JK; Lewis G; MacQueen G; Sahakian BJ; Kennedy SH; Lui JP; Mansur RB; McIntyre RS
    J Affect Disord; 2017 Mar; 210():57-65. PubMed ID: 28013123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired intuition in patients with major depressive disorder.
    Remmers C; Topolinski S; Dietrich DE; Michalak J
    Br J Clin Psychol; 2015 Jun; 54(2):200-13. PubMed ID: 25307321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and symptomatic correlates of interpersonal trauma in South Korean outpatients with major depressive disorder.
    Park SC; Kim D; Jang EY
    Compr Psychiatry; 2016 Apr; 66():46-52. PubMed ID: 26995235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Psychological and Cognitive Outcomes after Green versus Suburban Walking: A Pilot Crossover Study.
    de Brito JN; Pope ZC; Mitchell NR; Schneider IE; Larson JM; Horton TH; Pereira MA
    Int J Environ Res Public Health; 2019 Aug; 16(16):. PubMed ID: 31412602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-traumatic stress disorder and depression co-occurrence: Structural relations among disorder constructs and trait and symptom dimensions.
    Post LM; Feeny NC; Zoellner LA; Connell AM
    Psychol Psychother; 2016 Dec; 89(4):418-434. PubMed ID: 26643451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major depressive disorder and suicidal behavior among urban dwelling Ethiopian adult outpatients at a general hospital.
    Whittier AB; Gelaye B; Deyessa N; Bahretibeb Y; Kelkile TS; Berhane Y; Williams MA
    J Affect Disord; 2016 Jun; 197():58-65. PubMed ID: 26971124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort.
    Davis LL; Frazier EC; Gaynes BN; Trivedi MH; Wisniewski SR; Fava M; Barkin J; Kashner TM; Shelton RC; Alpert JE; Rush AJ
    J Clin Psychiatry; 2007 Dec; 68(12):1931-8. PubMed ID: 18162025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Walking the boundaries: using the 6-min walk test for accurate assessment of the level of fitness in breast clinic outpatients.
    Ying L; Yahng JJ; Fisher M; Simons K; Nightingale S
    ANZ J Surg; 2020 Jun; 90(6):1141-1145. PubMed ID: 31865637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting.
    Ishak WW; Balayan K; Bresee C; Greenberg JM; Fakhry H; Christensen S; Rapaport MH
    Qual Life Res; 2013 Apr; 22(3):585-96. PubMed ID: 22544416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the nonverbal communication of depression? Assessing expressive differences between depressive patients and healthy volunteers during clinical interviews.
    Fiquer JT; Moreno RA; Brunoni AR; Barros VB; Fernandes F; Gorenstein C
    J Affect Disord; 2018 Oct; 238():636-644. PubMed ID: 29957481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population.
    Kamat SA; Rajagopalan K; Pethick N; Willey V; Bullano M; Hassan M
    J Manag Care Pharm; 2008 Sep; 14(7):631-42. PubMed ID: 18774873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The self-perceived symptom distress and health-related conditions associated with morning to evening diurnal cortisol patterns in outpatients with major depressive disorder.
    Hsiao FH; Yang TT; Ho RT; Jow GM; Ng SM; Chan CL; Lai YM; Chen YT; Wang KC
    Psychoneuroendocrinology; 2010 May; 35(4):503-15. PubMed ID: 19775819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.